BrightGene Bio-Medical Technology Co., Ltd.

Quick facts

Phase 3 pipeline

• Drug: Placebo Administered SC
  Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.
• Drug: Semaglutide Administered SC · Diabetes, Obesity, Cardiovascular
  Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, suppress appetite, and promote weight loss.

Phase 2 pipeline

• BGM0504 Administered SC
• Semaglutide Administered SC

Phase 1 pipeline

• BGM0504 Injection multi-dose pen
• BGM0504 Injection single-dose pen
• BGM0504 tablets
• BGM1812

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• BrightGene Bio-Medical Technology Co., Ltd. portfolio CI brief
• BrightGene Bio-Medical Technology Co., Ltd. pipeline updates RSS